Cargando…
Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis
OBJECTIVES: Cardiovascular (CV) morbidity and mortality, and perpetuated synovial angiogenesis have been associated with RA. In our study we evaluated angiogenic factors in relation to vascular inflammation and function, and clinical markers in RA patients undergoing 1-year tofacitinib therapy. METH...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593522/ https://www.ncbi.nlm.nih.gov/pubmed/37871914 http://dx.doi.org/10.1093/rheumatology/kead502 |
_version_ | 1785124459244421120 |
---|---|
author | Kerekes, György Czókolyová, Monika Hamar, Attila Pusztai, Anita Tajti, Gábor Katkó, Mónika Végh, Edit Pethő, Zsófia Bodnár, Nóra Horváth, Ágnes Soós, Boglárka Szamosi, Szilvia Hascsi, Zsolt Harangi, Mariann Hodosi, Katalin Panyi, György Seres, Tamás Szűcs, Gabriella Szekanecz, Zoltán |
author_facet | Kerekes, György Czókolyová, Monika Hamar, Attila Pusztai, Anita Tajti, Gábor Katkó, Mónika Végh, Edit Pethő, Zsófia Bodnár, Nóra Horváth, Ágnes Soós, Boglárka Szamosi, Szilvia Hascsi, Zsolt Harangi, Mariann Hodosi, Katalin Panyi, György Seres, Tamás Szűcs, Gabriella Szekanecz, Zoltán |
author_sort | Kerekes, György |
collection | PubMed |
description | OBJECTIVES: Cardiovascular (CV) morbidity and mortality, and perpetuated synovial angiogenesis have been associated with RA. In our study we evaluated angiogenic factors in relation to vascular inflammation and function, and clinical markers in RA patients undergoing 1-year tofacitinib therapy. METHODS: Thirty RA patients treated with either 5 mg or 10 mg twice daily tofacitinib were included in a 12-month follow-up study. Eventually, 26 patients completed the study and were included in data analysis. Levels of various angiogenic cytokines (TNF-α, IL-6), growth factors [VEGF, basic fibroblast (bFGF), epidermal (EGF), placental (PlGF)], cathepsin K (CathK), CXC chemokine ligand 8 (CXCL8), galectin-3 (Gal-3) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) were determined at baseline, and at 6 and 12 months after initiating tofacitinib treatment. In order to assess flow-mediated vasodilation, common carotid intima-media thickness (ccIMT) and carotid-femoral pulse-wave velocity, ultrasonography was performed. Synovial and aortic inflammation was also assessed by (18)F-fluorodeoxyglucose-PET/CT. RESULTS: One-year tofacitinib therapy significantly decreased IL-6, VEGF, bFGF, EGF, PlGF and CathK, while it increased Gal-3 production (P < 0.05). bFGF, PlGF and NT-proBNP levels were higher, while platelet-endothelial cell adhesion molecule 1 (PECAM-1) levels were lower in RF-seropositive patients (P < 0.05). TNF-α, bFGF and PlGF correlated with post-treatment synovial inflammation, while aortic inflammation was rather dependent on IL-6 and PECAM-1 as determined by PET/CT (P < 0.05). In the correlation analyses, NT-proBNP, CXCL8 and Cath variables correlated with ccIMT (P < 0.05). CONCLUSIONS: Decreasing production of bFGF, PlGF or IL-6 by 1-year tofacitinib therapy potentially inhibits synovial and aortic inflammation. Although NT-proBNP, CXCL8 and CathK were associated with ccIMT, their role in RA-associated atherosclerosis needs to be further evaluated. |
format | Online Article Text |
id | pubmed-10593522 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105935222023-10-24 Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis Kerekes, György Czókolyová, Monika Hamar, Attila Pusztai, Anita Tajti, Gábor Katkó, Mónika Végh, Edit Pethő, Zsófia Bodnár, Nóra Horváth, Ágnes Soós, Boglárka Szamosi, Szilvia Hascsi, Zsolt Harangi, Mariann Hodosi, Katalin Panyi, György Seres, Tamás Szűcs, Gabriella Szekanecz, Zoltán Rheumatology (Oxford) Clinical Science OBJECTIVES: Cardiovascular (CV) morbidity and mortality, and perpetuated synovial angiogenesis have been associated with RA. In our study we evaluated angiogenic factors in relation to vascular inflammation and function, and clinical markers in RA patients undergoing 1-year tofacitinib therapy. METHODS: Thirty RA patients treated with either 5 mg or 10 mg twice daily tofacitinib were included in a 12-month follow-up study. Eventually, 26 patients completed the study and were included in data analysis. Levels of various angiogenic cytokines (TNF-α, IL-6), growth factors [VEGF, basic fibroblast (bFGF), epidermal (EGF), placental (PlGF)], cathepsin K (CathK), CXC chemokine ligand 8 (CXCL8), galectin-3 (Gal-3) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) were determined at baseline, and at 6 and 12 months after initiating tofacitinib treatment. In order to assess flow-mediated vasodilation, common carotid intima-media thickness (ccIMT) and carotid-femoral pulse-wave velocity, ultrasonography was performed. Synovial and aortic inflammation was also assessed by (18)F-fluorodeoxyglucose-PET/CT. RESULTS: One-year tofacitinib therapy significantly decreased IL-6, VEGF, bFGF, EGF, PlGF and CathK, while it increased Gal-3 production (P < 0.05). bFGF, PlGF and NT-proBNP levels were higher, while platelet-endothelial cell adhesion molecule 1 (PECAM-1) levels were lower in RF-seropositive patients (P < 0.05). TNF-α, bFGF and PlGF correlated with post-treatment synovial inflammation, while aortic inflammation was rather dependent on IL-6 and PECAM-1 as determined by PET/CT (P < 0.05). In the correlation analyses, NT-proBNP, CXCL8 and Cath variables correlated with ccIMT (P < 0.05). CONCLUSIONS: Decreasing production of bFGF, PlGF or IL-6 by 1-year tofacitinib therapy potentially inhibits synovial and aortic inflammation. Although NT-proBNP, CXCL8 and CathK were associated with ccIMT, their role in RA-associated atherosclerosis needs to be further evaluated. Oxford University Press 2023-10-23 /pmc/articles/PMC10593522/ /pubmed/37871914 http://dx.doi.org/10.1093/rheumatology/kead502 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Science Kerekes, György Czókolyová, Monika Hamar, Attila Pusztai, Anita Tajti, Gábor Katkó, Mónika Végh, Edit Pethő, Zsófia Bodnár, Nóra Horváth, Ágnes Soós, Boglárka Szamosi, Szilvia Hascsi, Zsolt Harangi, Mariann Hodosi, Katalin Panyi, György Seres, Tamás Szűcs, Gabriella Szekanecz, Zoltán Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis |
title | Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis |
title_full | Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis |
title_fullStr | Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis |
title_full_unstemmed | Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis |
title_short | Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis |
title_sort | effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593522/ https://www.ncbi.nlm.nih.gov/pubmed/37871914 http://dx.doi.org/10.1093/rheumatology/kead502 |
work_keys_str_mv | AT kerekesgyorgy effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT czokolyovamonika effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT hamarattila effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT pusztaianita effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT tajtigabor effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT katkomonika effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT veghedit effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT pethozsofia effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT bodnarnora effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT horvathagnes effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT soosboglarka effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT szamosiszilvia effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT hascsizsolt effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT harangimariann effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT hodosikatalin effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT panyigyorgy effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT serestamas effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT szucsgabriella effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis AT szekaneczzoltan effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis |